These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Medicines pricing singled out. Buchanan E S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941 [No Abstract] [Full Text] [Related]
4. Convergence of decision rules for value-based pricing of new innovative drugs. Gandjour A Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):209-13. PubMed ID: 25327543 [TBL] [Abstract][Full Text] [Related]
5. Differential pricing of new pharmaceuticals in lower income European countries. Kaló Z; Annemans L; Garrison LP Expert Rev Pharmacoecon Outcomes Res; 2013 Dec; 13(6):735-41. PubMed ID: 24219049 [TBL] [Abstract][Full Text] [Related]
6. Value-Based Pricing: Do Not Throw Away the Baby with the Bath Water. Neyt M Pharmacoeconomics; 2018 Jan; 36(1):1-3. PubMed ID: 28975551 [No Abstract] [Full Text] [Related]
7. Pricing schemes for new drugs: a welfare analysis. Levaggi R Soc Sci Med; 2014 Feb; 102():69-73. PubMed ID: 24565143 [TBL] [Abstract][Full Text] [Related]
8. Value based pricing for NHS drugs: an opportunity not to be missed? Claxton K; Briggs A; Buxton MJ; Culyer AJ; McCabe C; Walker S; Sculpher MJ BMJ; 2008 Feb; 336(7638):251-4. PubMed ID: 18244997 [TBL] [Abstract][Full Text] [Related]
9. Insurance against drug costs--a progress report. WILKINSON WA Am J Public Health Nations Health; 1960 May; 50(5):670-4. PubMed ID: 13844765 [No Abstract] [Full Text] [Related]
10. [Can drug consumption in general be reduced and can drug costs for insurance carriers be reduced?]. TOELKE S Pharm Prax; 1959; 10():149-53. PubMed ID: 13838637 [No Abstract] [Full Text] [Related]
12. Pharmaceutical price regulation and its impact on drug innovation: mitigating the trade-offs. Kakkar AK Expert Opin Ther Pat; 2021 Mar; 31(3):189-192. PubMed ID: 33435784 [No Abstract] [Full Text] [Related]
13. Pharmaceutical Pricing and Market Access Outlook Europe 2010-HealthNetwork Communications' fourth annual conference. 24-25 March 2010, London, UK. Ogbighele E IDrugs; 2010 May; 13(5):317-20. PubMed ID: 20432188 [TBL] [Abstract][Full Text] [Related]
14. Market watch: pricing strategies for emerging markets. Lineberry N; Snyder E; Gunda S Nat Rev Drug Discov; 2011 Aug; 10(8):567. PubMed ID: 21804586 [No Abstract] [Full Text] [Related]
15. Medicaid preferred drug lists: cost containment and side effects. Headen AE Pharmacoeconomics; 2006; 24 Suppl 3():1-3. PubMed ID: 17266384 [No Abstract] [Full Text] [Related]
16. [Pharmaceutical reference pricing in Germany: definition of therapeutic groups, price setting through regression procedure and effects]. Stargardt T; Schreyögg J; Busse R Gesundheitswesen; 2005 Jul; 67(7):468-77. PubMed ID: 16103970 [TBL] [Abstract][Full Text] [Related]
17. Pricing and reimbursement of pharmaceuticals in the Czech Republic and Sweden. Davidova J; Praznovcova L; Lundborg CS Pharm World Sci; 2008 Jan; 30(1):57-64. PubMed ID: 17588212 [TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical reference prices. How do they work in practice? Dickson M; Redwood H Pharmacoeconomics; 1998 Nov; 14(5):471-9. PubMed ID: 10344913 [TBL] [Abstract][Full Text] [Related]
19. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Ioannides-Demos LL; Ibrahim JE; McNeil JJ Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886 [TBL] [Abstract][Full Text] [Related]
20. A reply to "Who would benefit from average value-based pricing?". Levaggi R; Pertile P Health Econ; 2021 Sep; 30(9):2284-2286. PubMed ID: 34245084 [No Abstract] [Full Text] [Related] [Next] [New Search]